Silvan Tuerkcan
Stock Analyst at Citizens
(4.26)
# 400
Out of 5,143 analysts
176
Total ratings
48.28%
Success rate
17.57%
Average return
Main Sectors:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Reiterates: Market Outperform | $86 | $53.98 | +59.32% | 17 | Dec 23, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Market Outperform | $35 → $57 | $40.86 | +39.50% | 15 | Dec 11, 2025 | |
| NUVB Nuvation Bio | Maintains: Market Outperform | $8 → $10 | $5.46 | +83.15% | 5 | Nov 20, 2025 | |
| ENGN enGene Holdings | Maintains: Market Outperform | $18 → $21 | $9.67 | +117.17% | 5 | Nov 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Market Outperform | $29 → $21 | $13.16 | +59.57% | 14 | Nov 7, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Market Outperform | $6 → $8 | $4.84 | +65.29% | 14 | Nov 5, 2025 | |
| BNTC Benitec Biopharma | Maintains: Market Outperform | $20 → $22 | $10.72 | +105.22% | 14 | Nov 4, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Market Outperform | $12 → $6 | $1.37 | +337.96% | 7 | Sep 22, 2025 | |
| PHR Phreesia | Maintains: Market Outperform | $30 → $34 | $11.70 | +190.60% | 1 | Sep 8, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Market Outperform | $41 → $45 | $32.11 | +40.14% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $50 | $44.01 | +13.61% | 23 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $5.87 | +155.54% | 3 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $10 → $6 | $3.34 | +79.64% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $5.74 | +56.79% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $120 | $15.42 | +678.21% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $17 | $1.50 | +1,033.33% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $4 | $2.28 | +75.44% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $8.94 | +134.90% | 10 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.75 | - | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $3.96 | +51.52% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $70.13 | +299.29% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $10.56 | +70.45% | 1 | Jan 26, 2023 |
CRISPR Therapeutics AG
Dec 23, 2025
Reiterates: Market Outperform
Price Target: $86
Current: $53.98
Upside: +59.32%
Terns Pharmaceuticals
Dec 11, 2025
Maintains: Market Outperform
Price Target: $35 → $57
Current: $40.86
Upside: +39.50%
Nuvation Bio
Nov 20, 2025
Maintains: Market Outperform
Price Target: $8 → $10
Current: $5.46
Upside: +83.15%
enGene Holdings
Nov 12, 2025
Maintains: Market Outperform
Price Target: $18 → $21
Current: $9.67
Upside: +117.17%
Intellia Therapeutics
Nov 7, 2025
Maintains: Market Outperform
Price Target: $29 → $21
Current: $13.16
Upside: +59.57%
Taysha Gene Therapies
Nov 5, 2025
Maintains: Market Outperform
Price Target: $6 → $8
Current: $4.84
Upside: +65.29%
Benitec Biopharma
Nov 4, 2025
Maintains: Market Outperform
Price Target: $20 → $22
Current: $10.72
Upside: +105.22%
Jasper Therapeutics
Sep 22, 2025
Maintains: Market Outperform
Price Target: $12 → $6
Current: $1.37
Upside: +337.96%
Phreesia
Sep 8, 2025
Maintains: Market Outperform
Price Target: $30 → $34
Current: $11.70
Upside: +190.60%
IDEAYA Biosciences
Sep 8, 2025
Maintains: Market Outperform
Price Target: $41 → $45
Current: $32.11
Upside: +40.14%
Jul 29, 2025
Reiterates: Market Outperform
Price Target: $50
Current: $44.01
Upside: +13.61%
Jun 6, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $5.87
Upside: +155.54%
May 20, 2025
Maintains: Market Outperform
Price Target: $10 → $6
Current: $3.34
Upside: +79.64%
May 15, 2025
Reiterates: Market Outperform
Price Target: $9
Current: $5.74
Upside: +56.79%
May 9, 2025
Downgrades: Market Perform
Price Target: $120
Current: $15.42
Upside: +678.21%
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $17
Current: $1.50
Upside: +1,033.33%
Jan 8, 2025
Initiates: Market Outperform
Price Target: $4
Current: $2.28
Upside: +75.44%
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $8.94
Upside: +134.90%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.75
Upside: -
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $3.96
Upside: +51.52%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $70.13
Upside: +299.29%
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $10.56
Upside: +70.45%